AstraZeneca PLC ADRhedged(AZNH.US)

Company Encyclopedia

AstraZeneca PLC ADRhedged

AZNH.US

Shareholder

Ownership	%Owned	Share Chg	Report Date
No Data

News

AstraZeneca PLC ADR Underperforms Tuesday When Compared To Competitors

AstraZeneca PLC ADR (AZN) fell 4.71% to $89.94 on Tuesday, underperforming compared to competitors like Eli Lilly & Co. and Biogen Inc. The NASDAQ Composite Index dropped 2.39%, while AstraZeneca's stock closed 6.81% below its 52-week high of $96.51. Trading volume reached 11.1 million, surpassing the 50-day average of 6.5 million. This trading session was challenging for the overall stock market, with the Dow Jones Industrial Average also declining by 1.76%.

Dow Jones·Yesterday at 06:20

Dow Jones·Yesterday at 06:20

AstraZeneca To Delist ADRs From Nasdaq By January, Eyes Broader Investor Reach

AstraZeneca plans to delist its American Depositary Shares from Nasdaq and transition to a direct listing on the NYSE by January 30, 2026. This move aims to create a unified global listing structure, enhancing access for investors. Additionally, the European Medicines Agency has validated the marketing authorization application for AstraZeneca's breast cancer drug, Enhertu, which showed promising trial results. AstraZeneca shares fell 3.55% to $91.04 following the announcement.

benzinga_article·Yesterday at 00:47

benzinga_article·Yesterday at 00:47

European Shares Extend Losses As Greenland Tensions Escalate

European stocks fell on Tuesday, continuing losses after the U.S. deployed military aircraft to Greenland, escalating tensions with Denmark. The pan-European Stoxx 600 dropped 1%, with notable declines in the German DAX and France's CAC 40. In corporate news, Treatt shares rose 3% after a partnership announcement, while AstraZeneca fell 2.2% due to plans to delist from Nasdaq. Ibstock shares slumped 6% amid market uncertainty, while Renault's sales increased, boosting its stock by nearly 2%.

rttnews·Yesterday at 17:15

rttnews·Yesterday at 17:15

BUZZ-Abivax rises as another media report feeds M&A chatter

Shares of Abivax (ABVX.PA) rose 6% amid M&A speculation, following a report that AstraZeneca (AZN.L) offered approximately 176 euros ($205.85) per share. Analysts from Kepler Chevreux and ODDO BHF attributed the stock's volatility to this news. Previously, Eli Lillywas rumored to be preparing a 15 billion euro ($17.5 billion) bid, although France’s Finance Ministry has not received any formal investment request. Both AstraZeneca and Abivax did not provide immediate comments on the matter.

Reuters·Yesterday at 16:56

Reuters·Yesterday at 16:56